Skip to content

Virtual Environments in Patients Receiving Treatment for Cancer

The Effectiveness of Virtual Environment on the Adverse Psychological Effects in Patients Receiving Treatment for Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02392728
Acronym
VE
Enrollment
50
Registered
2015-03-19
Start date
2018-02-05
Completion date
2020-01-20
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mood Disturbances

Brief summary

The mood disturbances that lung cancer patients experience during and after chemotherapy have a debilitating effect on their quality of life. The goal of the proposed project is to develop and test an intervention that relies on the use of immersive Virtual Reality (VR) to combat the adverse psychological/emotional consequences of receiving treatment for cancer. Although VR has been used with success to treat various psychological conditions (e.g., phobias, PTSD), its potential in helping cancer patients experience an improved mood and hence better quality of life has not yet been tested. In this project the investigators will first develop the virtual content (e.g., natural scenes) that patients will experience within a Head-Mounted-Display, simulating movement by manipulating a gesture controller. The investigators will then carry out a randomized, double blind, crossover trial with 50 hospitalized cancer patients to test whether they can benefit psychologically and emotionally from their interaction with an immersive environment compared to those who will experience a guided imagery intervention. A positive result will open the route for the future development of affordable self-administered VR solutions for treating the psychological side-effects of cancer treatment.

Detailed description

Although VR has been used with success to treat various psychological conditions (e.g., phobias, PTSD), its potential in helping cancer patients experience an improved mood and hence better quality of life has not yet been tested. In this project the investigators will first develop the virtual content (e.g., natural scenes) that patients will experience within a Head-Mounted-Display, simulating movement by manipulating a gesture controller. The investigators will then carry out a randomized, double blind, crossover trial with 50 hospitalized cancer patients to test whether they can benefit psychologically and emotionally from their interaction with an immersive environment compared to those who will experience a guided imagery intervention. A positive result will open the route for the future development of affordable self-administered VR solutions for treating the psychological side-effects of cancer treatment.

Interventions

Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)

BEHAVIORALGuided Imagery

Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller

Sponsors

University of Cyprus
CollaboratorOTHER
Cyprus University of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients will be included if they had a histopathological diagnosis of cancer (different types are allowed) * were 18 years or older, on active treatment and were receiving care at the hospital as inpatients * Eligible participants will need to be able to speak and understand Greek and they had given written informed consent * Participants should also have a score of \>60 on the POMS total mood disturbance scale, a \>50 on the Karnofsky Performance Scale Index * a mean of \>50 on the Attentional Function Index (AFI)

Exclusion criteria

* Patients were excluded if they were receiving palliative care * they had an impaired cognitive ability or * they had an impaired visual ability

Design outcomes

Primary

MeasureTime frameDescription
Changes in Mood Disturbances as measured by the POMSBaseline and then participants will be followed for the duration of the intervention, an expected average of 8 daysThe POMS total mood disturbance comprises subscales that evaluate anxiety, depression, anger, vigor, fatigue, and confusion. The possible range of scores for the TMDS is -40 through 192 with higher scores indicating greater mood. Lower scores indicate an improvement in mood

Secondary

MeasureTime frameDescription
Changes in Quality of Life as measured by FACT-GBaseline and then participants will be followed for the duration of the intervention, an expected average of 8 daysFACT-G, is a self-report instrument consisting of 27-items
Changes in Blood PressureBaseline and then participants will be followed for the duration of the intervention, an expected average of 8 daysMeasurement of Blood Pressure
Changes in Heart RateBaseline and then participants will be followed for the duration of the intervention, an expected average of 8 daysMeasurement of Heart Rate

Countries

Cyprus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026